7 news items
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
APLS
10 Jun 24
destroy the retinal cells responsible for vision. The vision loss caused by GA severely impairs independence and quality of life by making it difficult
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
APLS
28 May 24
to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
APLD
APLS
CMI
16 May 24
is the attorney responsible for its content. Contact: Johnson Fistel, LLP 501 W. Broadway, Suite 800, San
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
APLS
7 May 24
by EMA is strictly procedural in response to the CJEU judgment and is not related to the pegcetacoplan data package
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
APLS
1 May 24
of response to treatment in eyes with geographic atrophy treated with Pegcetacoplan in a within-patient comparison using automated AI-based OCT biomarker
3rkuwhvvk 7vq9jci457jagygbgauz8p8xm774qm2kwdlxe
APLS
26 Apr 24
competing interests of experts. This decision by EMA is strictly procedural in response to the CJEU judgment and is not related
7x183mzm7n3r5ryglauqp5xnp kdyqwetr5os85k04vym3ljpgsbe
APLS
15 Apr 24
, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments
- Prev
- 1
- Next